Anti-Obesity Prescription Drugs Market Key Players Analysis 2031
The Anti-Obesity Prescription Drugs Market is expected to register a CAGR of 26% from 2023 to 2031, with a market size expanding from US$ XX million in 2023 to US$ XX Million by 2031.
The Anti-Obesity Prescription Drugs Market is categorized by mechanism of action into the following subsegments: Peripherally Acting Drugs, Centrally Acting Drugs. It further presents an analysis based on drug class, i.e., Bupropion and Naltrexone, Orlistat, Lorcaserin, Phentermine and Topiramate, Liraglutide, and distribution channel, i.e., Hospital Pharmacy, Retail Pharmacy, Online Pharmacy. Forecasts up to 2031 are provided. The global analysis is broken down at the regional level and major countries. The market evaluation is presented in US$ for the above segmental analysis.
Purpose of the ReportThe report Anti-Obesity Prescription Drugs Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
- Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
- Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
- Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.
Anti-Obesity Prescription Drugs Market Segmentation
Mechanism of Action- Peripherally Acting Drugs
- Centrally Acting Drugs
- Bupropion and Naltrexone
- Orlistat
- Lorcaserin
- Phentermine and Topiramate
- Liraglutide
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Strategic Insights
Anti-Obesity Prescription Drugs Market Growth Drivers- Excessive Rate of Obesity in the World: Rising prevalence of obesity worldwide created a craze for over-the-counter drugs to treat obesity and related disorders.
- FDA New prescription drug approvals: Regulation authorities like FDA approval of new prescription drugs are driving growth in the market as it offers patients with new options for treatment.
- Increased Recognition of Health Concerns: Increased recognition of health concerns that obesity has engulfed – from diabetes to heart disease to joint ailments – will only serve as an incentive for anti-obesity treatment.
- Trend Toward Personalized Medicine: Personalized medicine has to start with genetics and pharmacogenomics which pave the way towards individually tailored anti-obesity medications based on a patient’s genetic background.
- Combination Therapies: Combination therapies are in the research phase of drug companies to improve anti-obesity medications by targeting multiple factors that lead to weight gain.
- Non-Surgical Weight Loss Options: Increasing numbers of people are opting for non-surgical weight loss solutions, with a growing preference for drugs over procedures like bariatric surgery.
- Development of Safer, More Effective Drugs: One important area for innovation is about the development of safer, more effective prescription drugs for the treatment of obesity with fewer side effects.
- Access to New Markets: Growing markets characterized by growing levels of obesity provide pharmaceutical companies with an opportunity to gain access to the regions with anti-obesity drugs.
- Accessible through Over the Counter: With one such prospect is where some prescription drugs would be repackaged for over the counter sale and therefore could reach more people
Market Report Scope
Key Selling Points
- Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Anti-Obesity Prescription Drugs Market, providing a holistic landscape.
- Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
- Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
- Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.
The research report on the Anti-Obesity Prescription Drugs Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.
REGIONAL FRAMEWORK
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The market is expected to register a CAGR of 26% during 2021–2031.
The driving factors of the market are the global growth in obesity prevalence rates, developments in the formulation of effective drugs, and rising awareness about obesity-related diseases such as diabetes and heart problems.
Key trends in the market include combination drugs, personalized weight loss medicines, and the increasing use of non-invasive treatments such as oral and injectable drugs.
Key companies in this market are - Novo Nordisk (Saxenda), Eli Lilly (Wegovy), and Johnson & Johnson.
The report can be delivered in PDF/PPT format; we can also share excel dataset based on the request.
Some of the customization options available based on request are additional 3–5 company profiles and country-specific analysis of 3–5 countries of your choice. Customizations are to be requested/discussed before making final order confirmation, as our team would review the same and check the feasibility.
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Anti-Obesity Prescription Drugs Market - By Mechanism of Action
1.3.2 Anti-Obesity Prescription Drugs Market - By Drug Class
1.3.3 Anti-Obesity Prescription Drugs Market - By Distribution Channel
1.3.4 Anti-Obesity Prescription Drugs Market - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. ANTI-OBESITY PRESCRIPTION DRUGS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. ANTI-OBESITY PRESCRIPTION DRUGS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. ANTI-OBESITY PRESCRIPTION DRUGS MARKET - GLOBAL MARKET ANALYSIS
6.1. ANTI-OBESITY PRESCRIPTION DRUGS - GLOBAL MARKET OVERVIEW
6.2. ANTI-OBESITY PRESCRIPTION DRUGS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. ANTI-OBESITY PRESCRIPTION DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - MECHANISM OF ACTION
7.1. OVERVIEW
7.2. MECHANISM OF ACTION MARKET FORECASTS AND ANALYSIS
7.3. PERIPHERALLY ACTING DRUGS
7.3.1. Overview
7.3.2. Peripherally Acting Drugs Market Forecast and Analysis
7.4. CENTRALLY ACTING DRUGS
7.4.1. Overview
7.4.2. Centrally Acting Drugs Market Forecast and Analysis
8. ANTI-OBESITY PRESCRIPTION DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - DRUG CLASS
8.1. OVERVIEW
8.2. DRUG CLASS MARKET FORECASTS AND ANALYSIS
8.3. BUPROPION AND NALTREXONE
8.3.1. Overview
8.3.2. Bupropion and Naltrexone Market Forecast and Analysis
8.4. ORLISTAT
8.4.1. Overview
8.4.2. Orlistat Market Forecast and Analysis
8.5. LORCASERIN
8.5.1. Overview
8.5.2. Lorcaserin Market Forecast and Analysis
8.6. PHENTERMINE AND TOPIRAMATE
8.6.1. Overview
8.6.2. Phentermine and Topiramate Market Forecast and Analysis
8.7. LIRAGLUTIDE
8.7.1. Overview
8.7.2. Liraglutide Market Forecast and Analysis
9. ANTI-OBESITY PRESCRIPTION DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - DISTRIBUTION CHANNEL
9.1. OVERVIEW
9.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
9.3. HOSPITAL PHARMACY
9.3.1. Overview
9.3.2. Hospital Pharmacy Market Forecast and Analysis
9.4. RETAIL PHARMACY
9.4.1. Overview
9.4.2. Retail Pharmacy Market Forecast and Analysis
9.5. ONLINE PHARMACY
9.5.1. Overview
9.5.2. Online Pharmacy Market Forecast and Analysis
10. ANTI-OBESITY PRESCRIPTION DRUGS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Anti-Obesity Prescription Drugs Market Overview
10.1.2 North America Anti-Obesity Prescription Drugs Market Forecasts and Analysis
10.1.3 North America Anti-Obesity Prescription Drugs Market Forecasts and Analysis - By Mechanism of Action
10.1.4 North America Anti-Obesity Prescription Drugs Market Forecasts and Analysis - By Drug Class
10.1.5 North America Anti-Obesity Prescription Drugs Market Forecasts and Analysis - By Distribution Channel
10.1.6 North America Anti-Obesity Prescription Drugs Market Forecasts and Analysis - By Countries
10.1.6.1 United States Anti-Obesity Prescription Drugs Market
10.1.6.1.1 United States Anti-Obesity Prescription Drugs Market by Mechanism of Action
10.1.6.1.2 United States Anti-Obesity Prescription Drugs Market by Drug Class
10.1.6.1.3 United States Anti-Obesity Prescription Drugs Market by Distribution Channel
10.1.6.2 Canada Anti-Obesity Prescription Drugs Market
10.1.6.2.1 Canada Anti-Obesity Prescription Drugs Market by Mechanism of Action
10.1.6.2.2 Canada Anti-Obesity Prescription Drugs Market by Drug Class
10.1.6.2.3 Canada Anti-Obesity Prescription Drugs Market by Distribution Channel
10.1.6.3 Mexico Anti-Obesity Prescription Drugs Market
10.1.6.3.1 Mexico Anti-Obesity Prescription Drugs Market by Mechanism of Action
10.1.6.3.2 Mexico Anti-Obesity Prescription Drugs Market by Drug Class
10.1.6.3.3 Mexico Anti-Obesity Prescription Drugs Market by Distribution Channel
10.2. EUROPE
10.2.1 Europe Anti-Obesity Prescription Drugs Market Overview
10.2.2 Europe Anti-Obesity Prescription Drugs Market Forecasts and Analysis
10.2.3 Europe Anti-Obesity Prescription Drugs Market Forecasts and Analysis - By Mechanism of Action
10.2.4 Europe Anti-Obesity Prescription Drugs Market Forecasts and Analysis - By Drug Class
10.2.5 Europe Anti-Obesity Prescription Drugs Market Forecasts and Analysis - By Distribution Channel
10.2.6 Europe Anti-Obesity Prescription Drugs Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Anti-Obesity Prescription Drugs Market
10.2.6.1.1 Germany Anti-Obesity Prescription Drugs Market by Mechanism of Action
10.2.6.1.2 Germany Anti-Obesity Prescription Drugs Market by Drug Class
10.2.6.1.3 Germany Anti-Obesity Prescription Drugs Market by Distribution Channel
10.2.6.2 France Anti-Obesity Prescription Drugs Market
10.2.6.2.1 France Anti-Obesity Prescription Drugs Market by Mechanism of Action
10.2.6.2.2 France Anti-Obesity Prescription Drugs Market by Drug Class
10.2.6.2.3 France Anti-Obesity Prescription Drugs Market by Distribution Channel
10.2.6.3 Italy Anti-Obesity Prescription Drugs Market
10.2.6.3.1 Italy Anti-Obesity Prescription Drugs Market by Mechanism of Action
10.2.6.3.2 Italy Anti-Obesity Prescription Drugs Market by Drug Class
10.2.6.3.3 Italy Anti-Obesity Prescription Drugs Market by Distribution Channel
10.2.6.4 Spain Anti-Obesity Prescription Drugs Market
10.2.6.4.1 Spain Anti-Obesity Prescription Drugs Market by Mechanism of Action
10.2.6.4.2 Spain Anti-Obesity Prescription Drugs Market by Drug Class
10.2.6.4.3 Spain Anti-Obesity Prescription Drugs Market by Distribution Channel
10.2.6.5 United Kingdom Anti-Obesity Prescription Drugs Market
10.2.6.5.1 United Kingdom Anti-Obesity Prescription Drugs Market by Mechanism of Action
10.2.6.5.2 United Kingdom Anti-Obesity Prescription Drugs Market by Drug Class
10.2.6.5.3 United Kingdom Anti-Obesity Prescription Drugs Market by Distribution Channel
10.2.6.6 Rest of Europe Anti-Obesity Prescription Drugs Market
10.2.6.6.1 Rest of Europe Anti-Obesity Prescription Drugs Market by Mechanism of Action
10.2.6.6.2 Rest of Europe Anti-Obesity Prescription Drugs Market by Drug Class
10.2.6.6.3 Rest of Europe Anti-Obesity Prescription Drugs Market by Distribution Channel
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Anti-Obesity Prescription Drugs Market Overview
10.3.2 Asia-Pacific Anti-Obesity Prescription Drugs Market Forecasts and Analysis
10.3.3 Asia-Pacific Anti-Obesity Prescription Drugs Market Forecasts and Analysis - By Mechanism of Action
10.3.4 Asia-Pacific Anti-Obesity Prescription Drugs Market Forecasts and Analysis - By Drug Class
10.3.5 Asia-Pacific Anti-Obesity Prescription Drugs Market Forecasts and Analysis - By Distribution Channel
10.3.6 Asia-Pacific Anti-Obesity Prescription Drugs Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Anti-Obesity Prescription Drugs Market
10.3.6.1.1 Australia Anti-Obesity Prescription Drugs Market by Mechanism of Action
10.3.6.1.2 Australia Anti-Obesity Prescription Drugs Market by Drug Class
10.3.6.1.3 Australia Anti-Obesity Prescription Drugs Market by Distribution Channel
10.3.6.2 China Anti-Obesity Prescription Drugs Market
10.3.6.2.1 China Anti-Obesity Prescription Drugs Market by Mechanism of Action
10.3.6.2.2 China Anti-Obesity Prescription Drugs Market by Drug Class
10.3.6.2.3 China Anti-Obesity Prescription Drugs Market by Distribution Channel
10.3.6.3 India Anti-Obesity Prescription Drugs Market
10.3.6.3.1 India Anti-Obesity Prescription Drugs Market by Mechanism of Action
10.3.6.3.2 India Anti-Obesity Prescription Drugs Market by Drug Class
10.3.6.3.3 India Anti-Obesity Prescription Drugs Market by Distribution Channel
10.3.6.4 Japan Anti-Obesity Prescription Drugs Market
10.3.6.4.1 Japan Anti-Obesity Prescription Drugs Market by Mechanism of Action
10.3.6.4.2 Japan Anti-Obesity Prescription Drugs Market by Drug Class
10.3.6.4.3 Japan Anti-Obesity Prescription Drugs Market by Distribution Channel
10.3.6.5 South Korea Anti-Obesity Prescription Drugs Market
10.3.6.5.1 South Korea Anti-Obesity Prescription Drugs Market by Mechanism of Action
10.3.6.5.2 South Korea Anti-Obesity Prescription Drugs Market by Drug Class
10.3.6.5.3 South Korea Anti-Obesity Prescription Drugs Market by Distribution Channel
10.3.6.6 Rest of Asia-Pacific Anti-Obesity Prescription Drugs Market
10.3.6.6.1 Rest of Asia-Pacific Anti-Obesity Prescription Drugs Market by Mechanism of Action
10.3.6.6.2 Rest of Asia-Pacific Anti-Obesity Prescription Drugs Market by Drug Class
10.3.6.6.3 Rest of Asia-Pacific Anti-Obesity Prescription Drugs Market by Distribution Channel
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Anti-Obesity Prescription Drugs Market Overview
10.4.2 Middle East and Africa Anti-Obesity Prescription Drugs Market Forecasts and Analysis
10.4.3 Middle East and Africa Anti-Obesity Prescription Drugs Market Forecasts and Analysis - By Mechanism of Action
10.4.4 Middle East and Africa Anti-Obesity Prescription Drugs Market Forecasts and Analysis - By Drug Class
10.4.5 Middle East and Africa Anti-Obesity Prescription Drugs Market Forecasts and Analysis - By Distribution Channel
10.4.6 Middle East and Africa Anti-Obesity Prescription Drugs Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Anti-Obesity Prescription Drugs Market
10.4.6.1.1 South Africa Anti-Obesity Prescription Drugs Market by Mechanism of Action
10.4.6.1.2 South Africa Anti-Obesity Prescription Drugs Market by Drug Class
10.4.6.1.3 South Africa Anti-Obesity Prescription Drugs Market by Distribution Channel
10.4.6.2 Saudi Arabia Anti-Obesity Prescription Drugs Market
10.4.6.2.1 Saudi Arabia Anti-Obesity Prescription Drugs Market by Mechanism of Action
10.4.6.2.2 Saudi Arabia Anti-Obesity Prescription Drugs Market by Drug Class
10.4.6.2.3 Saudi Arabia Anti-Obesity Prescription Drugs Market by Distribution Channel
10.4.6.3 U.A.E Anti-Obesity Prescription Drugs Market
10.4.6.3.1 U.A.E Anti-Obesity Prescription Drugs Market by Mechanism of Action
10.4.6.3.2 U.A.E Anti-Obesity Prescription Drugs Market by Drug Class
10.4.6.3.3 U.A.E Anti-Obesity Prescription Drugs Market by Distribution Channel
10.4.6.4 Rest of Middle East and Africa Anti-Obesity Prescription Drugs Market
10.4.6.4.1 Rest of Middle East and Africa Anti-Obesity Prescription Drugs Market by Mechanism of Action
10.4.6.4.2 Rest of Middle East and Africa Anti-Obesity Prescription Drugs Market by Drug Class
10.4.6.4.3 Rest of Middle East and Africa Anti-Obesity Prescription Drugs Market by Distribution Channel
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Anti-Obesity Prescription Drugs Market Overview
10.5.2 South and Central America Anti-Obesity Prescription Drugs Market Forecasts and Analysis
10.5.3 South and Central America Anti-Obesity Prescription Drugs Market Forecasts and Analysis - By Mechanism of Action
10.5.4 South and Central America Anti-Obesity Prescription Drugs Market Forecasts and Analysis - By Drug Class
10.5.5 South and Central America Anti-Obesity Prescription Drugs Market Forecasts and Analysis - By Distribution Channel
10.5.6 South and Central America Anti-Obesity Prescription Drugs Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Anti-Obesity Prescription Drugs Market
10.5.6.1.1 Brazil Anti-Obesity Prescription Drugs Market by Mechanism of Action
10.5.6.1.2 Brazil Anti-Obesity Prescription Drugs Market by Drug Class
10.5.6.1.3 Brazil Anti-Obesity Prescription Drugs Market by Distribution Channel
10.5.6.2 Argentina Anti-Obesity Prescription Drugs Market
10.5.6.2.1 Argentina Anti-Obesity Prescription Drugs Market by Mechanism of Action
10.5.6.2.2 Argentina Anti-Obesity Prescription Drugs Market by Drug Class
10.5.6.2.3 Argentina Anti-Obesity Prescription Drugs Market by Distribution Channel
10.5.6.3 Rest of South and Central America Anti-Obesity Prescription Drugs Market
10.5.6.3.1 Rest of South and Central America Anti-Obesity Prescription Drugs Market by Mechanism of Action
10.5.6.3.2 Rest of South and Central America Anti-Obesity Prescription Drugs Market by Drug Class
10.5.6.3.3 Rest of South and Central America Anti-Obesity Prescription Drugs Market by Distribution Channel
11. IMPACT OF COVID-19 PANDEMIC ON GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET
11.1 North America
11.2 Europe
11.3 Asia-Pacific
11.4 Middle East and Africa
11.5 South and Central America
12. INDUSTRY LANDSCAPE
12.1. MERGERS AND ACQUISITIONS
12.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
12.3. NEW PRODUCT LAUNCHES
12.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
13. ANTI-OBESITY PRESCRIPTION DRUGS MARKET, KEY COMPANY PROFILES
13.1. BRISTOL-MYERS SQUIBB CO.
13.1.1. Key Facts
13.1.2. Business Description
13.1.3. Products and Services
13.1.4. Financial Overview
13.1.5. SWOT Analysis
13.1.6. Key Developments
13.2. TAKEDA PHARMACEUTICAL
13.2.1. Key Facts
13.2.2. Business Description
13.2.3. Products and Services
13.2.4. Financial Overview
13.2.5. SWOT Analysis
13.2.6. Key Developments
13.3. EISAI COMPANY
13.3.1. Key Facts
13.3.2. Business Description
13.3.3. Products and Services
13.3.4. Financial Overview
13.3.5. SWOT Analysis
13.3.6. Key Developments
13.4. GLAXOSMITHKLINE PLC
13.4.1. Key Facts
13.4.2. Business Description
13.4.3. Products and Services
13.4.4. Financial Overview
13.4.5. SWOT Analysis
13.4.6. Key Developments
13.5. PFIZER INC
13.5.1. Key Facts
13.5.2. Business Description
13.5.3. Products and Services
13.5.4. Financial Overview
13.5.5. SWOT Analysis
13.5.6. Key Developments
13.6. SHIONOGI USA INC
13.6.1. Key Facts
13.6.2. Business Description
13.6.3. Products and Services
13.6.4. Financial Overview
13.6.5. SWOT Analysis
13.6.6. Key Developments
13.7. VIVUS INC
13.7.1. Key Facts
13.7.2. Business Description
13.7.3. Products and Services
13.7.4. Financial Overview
13.7.5. SWOT Analysis
13.7.6. Key Developments
13.8. ZAFGEN INC
13.8.1. Key Facts
13.8.2. Business Description
13.8.3. Products and Services
13.8.4. Financial Overview
13.8.5. SWOT Analysis
13.8.6. Key Developments
13.9. NORGINE BV
13.9.1. Key Facts
13.9.2. Business Description
13.9.3. Products and Services
13.9.4. Financial Overview
13.9.5. SWOT Analysis
13.9.6. Key Developments
13.10. BOEHRINGER INGELHEIM GMBH.
13.10.1. Key Facts
13.10.2. Business Description
13.10.3. Products and Services
13.10.4. Financial Overview
13.10.5. SWOT Analysis
13.10.6. Key Developments
14. APPENDIX
14.1. ABOUT THE INSIGHT PARTNERS
14.2. GLOSSARY OF TERMS
1. BRISTOL-MYERS SQUIBB CO.
2. TAKEDA PHARMACEUTICAL
3. EISAI COMPANY
4. GLAXOSMITHKLINE PLC
5. PFIZER INC
6. SHIONOGI USA INC
7. VIVUS INC
8. ZAFGEN INC
9. NORGINE BV
10. BOEHRINGER INGELHEIM GMBH.
11. 7TM PHARMA
12. ZYDUS CADILA
13. AKRIMAX PHARMACEUTICALS
14. ZEALAND PHARMA
15. ARROWHEAD RESEARCH
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For